A RIP1 contender fails to make the cut at GSK after a fast fizzle in pancreatic cancer
Well, that didn’t last long.
Just months after GlaxoSmithKline jumped into a clinical program for its RIP1 kinase inhibitor GSK095 for pancreatic cancer, the program has been terminated.
There’s no explanation in the Q3 outline for what went wrong here beyond a note on portfolio prioritization, but the drug clearly didn’t live up to some early enthusiasm in GSK’s increasingly dominant oncology group under R&D chief Hal Barron.
“If clinical trials prove successful, this could be really promising for many people with end-stage disease,” noted George Miller, a professor at NYU Langone Health, last fall. Investigators had cited some stellar outcomes for the drug combined with checkpoints in mouse studies, which are often notoriously inaccurate. Scientists at NYU School of Medicine and its Perlmutter Cancer Center partnered with investigators at GSK on the study.
Barron has promised to be ruthless with his failures, slashing anything not on an apparent track to success. The only thing worse than a failure at GSK now is a slow failure.
So there’s that.